DT-202

About Dystrogen Therapeutics

Dystrogen Therapeutics is developing a first-in-class chimeric cell therapy platform with broad applications in genetic and degenerative disorders. Its core technology involves fusing donor and recipient cells to create 'Dystrophin Expressing Chimeric (DEC)' cells that evade immune rejection, eliminating the need for immunosuppression. The company is initially focused on Duchenne Muscular Dystrophy, with a Phase 1 trial underway, and has preclinical programs targeting sarcopenia, age-related muscle loss, and neurodegenerative diseases. Dystrogen's approach represents a potentially paradigm-shifting alternative to gene therapy and other advanced modalities.

Therapeutic Areas